Redefining microbiome-based therapeutics

MRM Health's proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into Optimized Synthetic Consortia through a proprietary optimization process and a unique manufacturing strategy as single Drug Substance.

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.

Microbiome experts

MRM Health is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research.

Corporate Video

Strong industrial and financial support

MRM Health has a corporate collaboration with DuPont Nutrition Biosciences in the discovery and development of microbiome-based therapeutics in the field of metabolic diseases. Other therapeutic areas are available for partnering. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB.

Our discovery engine

MRM Health combines a number of proprietary innovative technologies as its discovery engine. This includes direct access to the most advanced simulator of the human gut, the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®). In addition, through strategic partnerships with international research centers, MRM Health has secured extensive complementary microbiome and bioinformatics capabilities and taps into a multidisciplinary knowhow in inflammatory diseases and patient insights.

Optimized Synthetic Consortia

Through its proprietary technology platform, MRM Health develops Optimized Synthetic Consortia, a novel class of microbial therapeutics with strong advantages above the existing therapeutic approaches. Using a bioinformatics-guided in-human discovery engine, key therapeutic strains are identified and integrated into Optimized Synthetic Consortia. These are then manufactured as single Drug Substance.

Microbiome synthetic consortia

Advantages of Optimized Synthetic Consortia

Proprietary optimization and manufacturing as single Drug Substance
Faster onset-of-action
Robust and superior functional responses
Scalable manufacturing with reduced complexity and Cost of Goods
Differentiating regulatory status

Read more

Partnership with VIB, KU Leuven and UGent

VIB is an excellence-based entrepreneurial research institute in life sciences that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. VIB works in close partnership with Flemish universities, including KU Leuven and Ghent University.

In the news

MRM Health presents its proprietary microbiome therapeutics optimization technology at the Microbiome Movement Drug Development Conference

Read more